Endeavour sees recovery in intermediates sector

By Gareth Macdonald

- Last updated on GMT

Related tags: Mergers and acquisitions

Drug industry demand for chemical intermediates and development projects has rebounded significantly in the last 12 months according to UK group Endeavour Specialty Chemicals.

Speaking with in-Pharmatechnologist at CPhI 2010 in Paris Endeavour sales manager Jordi Robinson explained that, while the economic downturn and drug industry destocking impacted demand for bulk intermediates the market is recovering.

Robinson suggested that mergers and acquisitions, and subsequent integration efforts, have seen many drug firms reduce in-house capabilities in favour of outsourced chemical intermediate development and production.

Globalisation is also a factor in the recovery according to Robinson who added that, while the intermediates development sector is expanding in Asia, at present European and US suppliers are still favoured for the majority of projects.

However, he warned that, looking forward, European and US suppliers are unlikely to be able to compete on price unless they also invest in cutting-edge chemical intermediate development technology.

Related news

Related products

show more

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

SQ-USP-Brochure-Thumb-AP-CC

NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

Related suppliers

Follow us

Products

View more